IP Library › Patent Application 16710551
Patent Application
App. No. 16/710,551

METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/710,551
Abstract

Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of an IMiD® immunomodulatory drug to a patient having a cancer.

Claims (7)

1 . A method for treating hepatocellular carcinoma, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomers, tautomer, or isotopologue thereof in combination with an effective amount of an IMiD® immunomodulatory drug to a patient having hepatocellular carcinoma.

2 . The method of claim 1 , wherein the hepatocellular carcinoma is a hepatocellular carcinoma associated with the pathways involving mTOR, PI3K, or Akt kinases and mutants or isoforms thereof.

3 . The method of claim 1 , wherein the IMiD® immunomodulatory drug is lenalidomide.

4 . The method of claim 1 , wherein the IMiD® immunomodulatory drug is pomalidomide.

5 . The method of claim 1 , wherein the IMiD® immunomodulatory drug is (S)-3-(4-(4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, N-[2-(2,6-Dioxo-piperidin-3-yl)-1-oxo2,3-dihydro-1H-isoindol-4-ylmethyl]-2-phenyl-acetamide, 2-(2,6-Dioxopiperidin-3-yl)-4-phenylaminoisoindole-1,3-dione, 2-[2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylamino]-N-methylacetamide, 1-[2-(2,6-Dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-p-tolyl-urea, or N-[2-(2,6-Dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-pyridin-4-yl-acetamide.

6 . The method of claim 1 , further comprising the administration of an anti-CD20 antibody.

7 . The method of claim 6 , wherein anti-CD20 antibody is rituximab.